Total item
Cart Subtotal
$0.00 Customer Appreciation Sale.
15% off with promo code "APPRECIATION2023" on check out or purchase order
- Majid Momeny, .et al. Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells, Life Sci, 2021, Dec 15;287:120100 PMID: 34715143
- Majid Momeny, .et al. Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells, Eur J Pharmacol, 2020, 882:173298
Biological Activity
Cediranib (AZD2171) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.
Targets
| Target | Value |
|---|---|
| VEGFR2/KDR | IC50: 0.5nM |
| c-Kit | IC50: 2nM |
| VEGFR3/FLT4 | IC50: <=3nM |
| VEGFR1/FLT1 | IC50: 5nM |
| PDGFRβ | IC50: 5nM |
| FGFR1 | IC50: 26nM |
| PDGFRα | IC50: 36nM |
| CSF-1R | IC50: 110nM |
| Src | IC50: 130nM |
| Abl | IC50: 260nM |
| FLT3 | IC50: >1μM |
| HER2/ErbB2 | IC50: >1μM |
| CDK2 | IC50: >1μM |
| CDK4 | IC50: >1μM |
| EGFR | IC50: 1.6μM |
| AuroraA | IC50: >10μM |
| AuroraB | IC50: >10μM |
| MEK | IC50: >10μM |
| In vitro (25°C) | DMSO | 80 mg/mL (177.57 mM) | |
| Water | Insoluble | ||
| Ethanol | Insoluble | ||
| In vivo | 5% DMSO+50% PEG 300+5% Tween+ddH2O | 4 mg/mL | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 22.2 mL | 110.99 mL | 221.98 mL |
| 0.5 mM | 4.44 mL | 22.2 mL | 44.4 mL |
| 1 mM | 2.22 mL | 11.1 mL | 22.2 mL |
| 5 mM | 0.44 mL | 2.22 mL | 4.44 mL |
*The above data is based on the productmolecular weight 450.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Catalog Num | A10185 |
|---|---|
| Actions | Inhibitor |
| CAS No. | 288383-20-0 |
| Formula | C25H27FN4O3 |
| M. Wt | 450.5 |
| Purity | >98% |
| Synonyms | Recentin |
| SMILES | CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5 |
| Storage | Store lyophilized at -20ºC, keep desiccated. |
Datasheet
Product Tags
Product Questions
Product Questions
No Questions
You may also be interested in the following product(s)
Vandetanib (ZD6474)
Vandetanib (Zactima) is a VEGFR and EGFR antagonist and a tyrosine kinase inhibitor with IC50 of 60, 90, 40 nM for HUVEC proliferation, PC-9…
Apatinib (YN968D1)
Apatinib (YN968D1) is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also …
Motesanib (AMG706)
Motesanib (AMG706) is a multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors (PDGFRs), an…
Brivanib (BMS-540215)
Brivanib (BMS-540215) is a VEGFR -2 inhibitor with an IC50 of 25 nM and Ki of 26 nM.
BMS-690514
BMS-690514 is a potent and selective inhibitor of epidermal growth factor receptor (EGFR), HER2, and HER4, as well as the VEGF receptor kina…
E-3810
E-3810 is a potent and selective dual inhibitor of VEGF and FGF receptors with IC50 values of 7 nM, 25 nM, 10 nM, 17.5 nM and 82.5 nM for VE…
Regorafenib (BAY 73-4506)
Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an ora…
Raf265 derivative
Raf265 derivative is a derivative of Raf265 that is an oral, highly selective RAF and VEGFR kinase inhibitor with IC50 of of 5 to 10 μM.
Keywords:buy Cediranib (AZD2171) | Cediranib (AZD2171) Supplier | purchase | cost | manufacturer | order | distributor | buy 288383-20-0| 288383-20-0 Supplier | purchase 288383-20-0 | 288383-20-0 cost | 288383-20-0 manufacturer | order 288383-20-0 | 288383-20-0 distributor
Adooq Quality Guarantee
We promise all products perform as described.